Privia Health Group, Inc. (NASDAQ:PRVA – Get Free Report) CEO Parth Mehrotra sold 15,647 shares of the company’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $22.64, for a total transaction of $354,248.08. Following the transaction, the chief executive officer directly owned 434,357 shares of the company’s stock, valued at approximately $9,833,842.48. This trade represents a 3.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Parth Mehrotra also recently made the following trade(s):
- On Monday, May 11th, Parth Mehrotra sold 105,439 shares of Privia Health Group stock. The shares were sold at an average price of $22.55, for a total value of $2,377,649.45.
- On Monday, March 16th, Parth Mehrotra sold 26,509 shares of Privia Health Group stock. The shares were sold at an average price of $22.11, for a total value of $586,113.99.
- On Friday, March 13th, Parth Mehrotra sold 27,229 shares of Privia Health Group stock. The stock was sold at an average price of $21.52, for a total transaction of $585,968.08.
- On Thursday, March 12th, Parth Mehrotra sold 26,763 shares of Privia Health Group stock. The stock was sold at an average price of $21.90, for a total transaction of $586,109.70.
- On Tuesday, March 10th, Parth Mehrotra sold 21,097 shares of Privia Health Group stock. The stock was sold at an average price of $22.71, for a total value of $479,112.87.
- On Monday, March 9th, Parth Mehrotra sold 41,999 shares of Privia Health Group stock. The stock was sold at an average price of $22.86, for a total value of $960,097.14.
- On Friday, March 6th, Parth Mehrotra sold 21,440 shares of Privia Health Group stock. The shares were sold at an average price of $23.15, for a total transaction of $496,336.00.
Privia Health Group Stock Down 1.7%
Shares of PRVA opened at $22.63 on Thursday. The stock has a market cap of $2.85 billion, a P/E ratio of 141.45, a P/E/G ratio of 1.69 and a beta of 0.96. The business’s 50 day moving average price is $22.65 and its 200-day moving average price is $23.25. Privia Health Group, Inc. has a 52 week low of $18.77 and a 52 week high of $26.51.
Institutional Trading of Privia Health Group
Large investors have recently modified their holdings of the company. PNC Financial Services Group Inc. increased its position in shares of Privia Health Group by 8.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 10,361 shares of the company’s stock valued at $213,000 after purchasing an additional 840 shares during the last quarter. Van Berkom & Associates Inc. increased its stake in Privia Health Group by 5.4% in the 1st quarter. Van Berkom & Associates Inc. now owns 4,053,043 shares of the company’s stock worth $83,371,000 after buying an additional 208,787 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Privia Health Group by 6.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,406,717 shares of the company’s stock valued at $49,500,000 after purchasing an additional 142,679 shares during the period. SEB Asset Management AB bought a new stake in shares of Privia Health Group during the first quarter valued at approximately $505,000. Finally, Future Fund LLC lifted its stake in Privia Health Group by 48.0% in the 1st quarter. Future Fund LLC now owns 65,538 shares of the company’s stock worth $1,348,000 after purchasing an additional 21,247 shares in the last quarter. Institutional investors own 94.48% of the company’s stock.
Analyst Ratings Changes
Several brokerages recently commented on PRVA. Truist Financial increased their price objective on shares of Privia Health Group from $31.00 to $33.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Barclays raised their price target on shares of Privia Health Group from $23.00 to $25.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 25th. Jefferies Financial Group reiterated a “buy” rating and set a $32.00 target price on shares of Privia Health Group in a research note on Thursday, February 26th. Citigroup decreased their price target on Privia Health Group from $34.00 to $32.00 and set a “buy” rating for the company in a research note on Tuesday, March 3rd. Finally, Weiss Ratings cut Privia Health Group from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, May 8th. Eleven investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $31.23.
Check Out Our Latest Report on PRVA
About Privia Health Group
Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.
Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.
Read More
- Five stocks we like better than Privia Health Group
- Airplane Maintenance Companies That Keep Flights Moving Are Ready to Soar
- Oklo Stock Could Be Ready for Another Massive Run
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
Receive News & Ratings for Privia Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Privia Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
